AMA Statement on updated COVID-19 boosters

Translate to Spanish or other 102 languages!

“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses."  Image for illustration purposes
“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses.” Image for illustration purposes

Mega Doctor News

- Advertisement -
Sandra Adamson Fryhofer, M.D.
Image Source: ama-assn.org

The following statement is attributable to:
Sandra Adamson Fryhofer, M.D.
Board Chair, American Medical Association

“Given that the BA.5 Omicron subvariant is responsible for the majority of COVID-19 infections currently circulating throughout the U.S., we welcome today’s recommendations by the Advisory Committee on Immunization Practices (ACIP) supporting a bivalent booster dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines—targeting the BA.4/BA.5 Omicron subvariants as well as the original variant. ACIP’s recommendations, following the U.S. Food and Drug Administration’s (FDA) authorization on Wednesday, will allow individuals 12 years and older to receive a booster dose of Pfizer’s bivalent vaccine and anyone 18 years and older to receive a booster dose of Moderna’s bivalent vaccine at least two months after completing their primary vaccine series or their most recent booster. The bivalent booster recommendation replaces previous booster recommendations with a monovalent booster dose for people ages 12 years and older.

“With COVID-19 infections continuing to impact the U.S. population and an increase in infections expected this fall and winter, data shows that the updated bivalent vaccines will increase immune response and help provide protection against severe COVID-19 outcomes including hospitalization and death. Vaccine effectiveness against SARS-CoV-2 infection wanes over time and vaccine booster doses have been shown to increase protection. With the highly transmissible Omicron variant continuing to evolve, broad update of a bivalent booster dose will help provide an additional layer of protection and could prevent more than 100,000 hospitalizations compared to a later roll-out.”

- Advertisement -

“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses, to protect themselves and their loved ones from severe complications, hospitalization, and death. Anyone with questions about the vaccines should speak with their physician and review trusted resources, including getvaccineanswers.org.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Study Reveals Link Between Parent and Child Weight Is Mostly Genetic

The link between parents’ body mass index (BMI) and their children’s BMI in childhood is driven largely by genetic inheritance, rather than by any direct biological effects of parental weight during pregnancy, a new study suggests.

Dr. Michael Seawell Discusses Renal Denervation for Difficult-to-Control High Blood Pressure

Dr. Michael Seawell, a board-certified interventional cardiologist at DHR Health, is helping expand access to renal denervation, a minimally invasive treatment designed for patients with difficult-to-control high blood pressure.

DHR Health Continues to Lead the Way in Treatment of Alzheimer’s Disease for the RGV

Two years after DHR Health announced it was the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved intravenous treatment for early Alzheimer’s disease, DHR Health continues to expand access to advanced Alzheimer’s care for patients in the Rio Grande Valley being now the only facility doing amyloid PET Scans, a diagnostic test to accurately diagnose Alzheimer’s disease. DHR Health also offers Kisunla, another FDA-approved intravenous treatment for early symptomatic Alzheimer’s disease.

The Genetic Armor Defeating Colorectal Cancer

A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University, and institutions across the U.S., have published a landmark paper on the role of TGFBR1*6A, a naturally occurring genetic mutation in the TGFBR1 gene found in approximately 14 percent of the general population. Image for illustration purposes
- Advertisement -